August 3, 2016
(UPI) – A potential vaccine for the Zika virus has entered early clinical trials to assess its safety in humans, U.S. health officials announced Wednesday. The DNA-based vaccine contains genetic pieces of the Zika virus. It is intended to promote an immune response that would protect against the mosquito-borne virus that can cause devastating birth defects, according to a statement from the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.